Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 5, 2012, Pages 467-473

  Mason, R Preston ^a,b   Jacob, Robert F ^a   Kubant, Ruslan ^c   Ciszewski, Aleksander ^c   Corbalan, J Jose ^c   Malinski, Tadeusz ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ELUCIDA RESEARCH LLC   (United States)

^c OHIO UNIVERSITY   (United States)

Author keywords

endothelium; hypertension; nitric oxide; nitric oxide synthase; saxagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GASTRIC INHIBITORY POLYPEPTIDE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; NITRIC OXIDE; SAXAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPERTENSION; INSULIN BLOOD LEVEL; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE;

ADAMANTANE; ANIMALS; AORTA; BLOOD PRESSURE; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOTHELIUM, VASCULAR; GLUCOSE TOLERANCE TEST; HYPERTENSION; INSULIN; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY GLOMERULUS; MALE; NITRIC OXIDE; PEROXYNITROUS ACID; RATS; RATS, ZUCKER;

EID: 84870053428     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31826be204     Document Type: Article

References (39)

1. Harrison DG, Freiman PC, Armstrong ML, et al. Alterations of vascular reactivity in atherosclerosis. Circ Res. 1987;61:74-80.
2. Liao JK. Endothelium and acute coronary syndromes. Clin Chem. 1998;44:1799-1808. (Pubitemid 28368900)
3. Grattagliano I, Palmieri VO, Portincasa P, et al. Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem. 2008;19:491-504. (Pubitemid 351952322)
4. Kurioka S, Koshimura K, Murakami Y, et al. Reverse correlation between urine nitric oxide metabolites and insulin resistance in patients with type 2 diabetes mellitus. Endocr J. 2000;47:77-81.
5. Mason RP, Kubant R, Jacob RF, et al. Loss of arterial and renal nitric oxide bioavailability in hypertensive rats with diabetes. Am J Hypertens. 2009;22:1160-1166.
6. Node K, Kitakaze M, Yoshikawa H, et al. Reduced plasma concentrations of nitrogen oxide in individuals with essential hypertension. Hypertension. 1997;30:405-408. (Pubitemid 27446100)
7. Shankar RR, Wu Y, Shen HQ, et al. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes. 2000;49:684-687. (Pubitemid 30339980)
8. Sydow K, Mondon CE, Schrader J, et al. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity. Arterioscler Thromb Vasc Biol. 2008;28:692-697. (Pubitemid 351651348)
9. Marfella R, Esposito K, Giunta R, et al. Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation. 2000;101:2247-2251. (Pubitemid 30317125)
10. Tong S, Neboori HJ, Tran ED, et al. Constitutive expression and enzymatic cleavage of ICAM-1 in the spontaneously hypertensive rat. J Vasc Res. 2011;48:386-396.
11. Komatsu S, Panes J, Russell JM, et al. Effects of chronic arterial hypertension on constitutive and induced intercellular adhesion molecule-1 expression in vivo. Hypertension. 1997;29:683-689. (Pubitemid 27074737)
12. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001;104:1336-1342. (Pubitemid 32880144)
13. Rohde LE, Lee RT, Rivero J, et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 1998;18:1765-1770. (Pubitemid 28521067)
14. Fura A, Khanna A, Vyas V, et al. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections. Drug Metab Dispos. 2009;37:1164-1171.
15. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009;26:249-262.
16. Conarello SL, Li Z, Ronan J, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci U S A. 2003;100:6825-6830. (Pubitemid 36666664)
17. Kim D, Kowalchick JE, Brockunier LL, et al. Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from betaaminoamides bearing subsituted triazolopiperazines. J Med Chem. 2008;51:589-602. (Pubitemid 351252287)
18. Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem. 2004;47:4135-4141. (Pubitemid 39045417)
19. Pacheco BP, Crajoinas RO, Couto GK, et al. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens. 2011;29:520-528.
20. Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48:592-598. (Pubitemid 351503521)
21. Mason RP, Jacob RF, Kubant R, et al. Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb. 2011;18:774-783.
22. Lvovich V, Scheeline A. Amperometric sensors for simultaneous superoxide and hydrogen peroxide detection. Anal Chem. 1997;69:454-462.
23. Malinski T, Taha Z. Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor. Nature. 1992;358:676-678.
24. McIntyre M, Hamilton CA, Rees DD, et al. Sex differences in the abundance of endothelial nitric oxide in a model of genetic hypertension. Hypertension. 1997;30:1517-1524. (Pubitemid 27528098)
25. Susanne K, Brosnan MJ, McIntyre M, et al. Superoxide anion production is increased in a model of genetic hypertension: role of the endothelium. Hypertension. 1999;33:1353-1358. (Pubitemid 29282653)
26. Bouloumie A, Bauersachs J, Ling W, et al. Endothelial dysfunction coincides with an enhanced nitric oxide synthase expression and superoxide anion production. Hypertension. 1997;30:934-941. (Pubitemid 27441125)
27. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003;111:1201-1209. (Pubitemid 36519937)
28. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148. (Pubitemid 24176909)
29. Fujii H, Takiuchi S, Kawano Y, et al. Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Am J Hypertens. 2008;21:650-656. (Pubitemid 351733378)
30. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail. 2004;6:261-268. (Pubitemid 38253044)
31. Brandt I, Lambeir AM, Ketelslegers JM, et al. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem. 2006;52:82-87. (Pubitemid 43032470)
32. Gomez N, Touihri K, Matheeussen V, et al. Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure. Eur J Heart Fail. 2012;14:14-21.
33. Fujimoto M, Shimizu N, Kunii K, et al. A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes. 2005;54:1340-1348. (Pubitemid 40586662)
34. Baron AD, Tarshoby M, Hook G, et al. Interaction between insulin sensitivity and muscle perfusion on glucose uptake in human skeletal muscle: evidence for capillary recruitment. Diabetes. 2000;49:768-774. (Pubitemid 30339992)
35. Steinberg HO, Brechtel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest. 1994;94:1172-1179.
36. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287:1420-1426. (Pubitemid 34250505)
37. Rask-Madsen C, Ihlemann N, Krarup T, et al. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes. 2001;50:2611-2618. (Pubitemid 33642782)
38. Taddei S, Virdis A, Mattei P, et al. Effect of insulin on acetylcholineinduced vasodilation in normotensive subjects and patients with essential hypertension. Circulation. 1995;92:2911-2918.
39. Westerbacka J, Bergholm R, Tiikkainen M, et al. Glargine and regular human insulin similarly acutely enhance endothelium-dependent vasodilatation in normal subjects. Arterioscler Thromb Vasc Biol. 2004;24:320-324. (Pubitemid 38197585)